Abstract 3449: Development of small molecule Bcl-XL inhibitors for treatment of lung cancer.
Dongkyoo Park(Central South University), Xingming Deng(Emory University), Gabriel Sica(Emory University), Walter J. Curran(Piedmont Cancer Institute), Andrew T. Magis(Institute for Systems Biology), Shi‐Yong Sun(Emory University), Fadlo R. Khuri(American University of Beirut Medical Center), Suresh S. Ramalingam(Emory University), Rui Li(Xuzhou Medical College), Taofeek K. Owonikoko(UPMC Hillman Cancer Center)
Cited by 0
Related Papers
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
|The Lancet|2004|2.4k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
|Journal of Clinical Oncology|2013|1.1k